BR112015023060A2 - entidades químicas - Google Patents

entidades químicas

Info

Publication number
BR112015023060A2
BR112015023060A2 BR112015023060A BR112015023060A BR112015023060A2 BR 112015023060 A2 BR112015023060 A2 BR 112015023060A2 BR 112015023060 A BR112015023060 A BR 112015023060A BR 112015023060 A BR112015023060 A BR 112015023060A BR 112015023060 A2 BR112015023060 A2 BR 112015023060A2
Authority
BR
Brazil
Prior art keywords
chemical entities
compositions
treatment
œchemical
entitiesâ
Prior art date
Application number
BR112015023060A
Other languages
English (en)
Other versions
BR112015023060B1 (pt
Inventor
Joaquín Lopez Contreras Andrés
Blanco Aparicio Carmen
Varela Busto Carmen
Álvaro Cebrían Muñoz David
Pastor Fernández Joaquín
Ignacio TOLEDO LÁZARO Luis
NIETO SOLER María
del Rosario RICO FERREIRA María
Murga Costa Matilde
Renner Oliver
Fernández-Capetillo Ruiz Oscar
Martínez González Sonia
RODRÍGUEZ ARÍSTEGUÍ Sonsoles
Original Assignee
Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023060(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii filed Critical Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii
Publication of BR112015023060A2 publication Critical patent/BR112015023060A2/pt
Publication of BR112015023060B1 publication Critical patent/BR112015023060B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

resumo da patente de invenã§ã£o para: “entidades quãmicas”. sã£o fornecidas entidades quã­micas selecionadas a partir de compostos de fã³rmula (i), em que r1, r2 e m tãªm os significados indicados na descriã§ã£o, e os sais, solvatos e estereoisã´meros farmaceuticamente aceitã¡veis dos mesmos, que sã£o inibidores de atr e sã£o potencialmente ãºteis no tratamento de cã¢ncer. sã£o ainda proporcionadas composiã§ãµes farmacãªuticas das entidades quã­micas, produtos de combinaã§ã£o que contãªm as entidades quã­micas, uso das composiã§ãµes como agentes terapãªuticos, e mã©todos de tratamento utilizando essas composiã§ãµes.
BR112015023060-1A 2013-03-15 2014-03-14 Entidades químicas BR112015023060B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382089 2013-03-15
EP13382089.4 2013-03-15
PCT/GB2014/050825 WO2014140644A1 (en) 2013-03-15 2014-03-14 Chemical entities

Publications (2)

Publication Number Publication Date
BR112015023060A2 true BR112015023060A2 (pt) 2017-07-18
BR112015023060B1 BR112015023060B1 (pt) 2022-07-05

Family

ID=48013903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023060-1A BR112015023060B1 (pt) 2013-03-15 2014-03-14 Entidades químicas

Country Status (32)

Country Link
US (1) US9453031B2 (pt)
EP (1) EP2970332B1 (pt)
JP (1) JP6379115B2 (pt)
KR (1) KR102206318B1 (pt)
CN (1) CN105051047B (pt)
AR (1) AR095443A1 (pt)
AU (1) AU2014229735B2 (pt)
BR (1) BR112015023060B1 (pt)
CA (1) CA2904768C (pt)
CL (1) CL2015002591A1 (pt)
CY (1) CY1120619T1 (pt)
DK (1) DK2970332T3 (pt)
EA (1) EA029771B1 (pt)
ES (1) ES2670674T3 (pt)
HK (1) HK1215021A1 (pt)
HR (1) HRP20180839T1 (pt)
HU (1) HUE037685T2 (pt)
IL (1) IL240708B (pt)
LT (1) LT2970332T (pt)
MX (1) MX368056B (pt)
NO (1) NO2970332T3 (pt)
NZ (1) NZ711038A (pt)
PE (1) PE20152007A1 (pt)
PH (1) PH12015502159B1 (pt)
PL (1) PL2970332T3 (pt)
PT (1) PT2970332T (pt)
RS (1) RS57216B1 (pt)
SG (1) SG11201507555PA (pt)
SI (1) SI2970332T1 (pt)
TW (1) TWI557131B (pt)
UA (1) UA118261C2 (pt)
WO (1) WO2014140644A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
NZ710079A (en) 2013-01-15 2020-01-31 Incyte Holdings Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
AR097431A1 (es) 2013-08-23 2016-03-16 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de quinasas pim
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017202748A1 (en) * 2016-05-24 2017-11-30 Merck Patent Gmbh Tricyclic heterocylic derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3090330A1 (en) * 2018-02-07 2019-08-15 Shijiazhuang Sagacity New Drug Development Co., Ltd. Atr inhibitor and application thereof
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
WO2021143821A1 (zh) * 2020-01-17 2021-07-22 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
JP2023545196A (ja) 2020-10-16 2023-10-26 シャンハイ ドーァ ノボ ファーマテック カンパニー，リミティド 三複素環誘導体、その医薬組成物及び使用
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115286645A (zh) * 2022-08-16 2022-11-04 南京雷正医药科技有限公司 三环杂环衍生物及其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
AU3427093A (en) * 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
JP4367866B2 (ja) 1997-02-12 2009-11-18 ザ リージェンツ オブ ジ ユニバーシティ オブ ミシガン 肺癌用のタンパク質マーカーおよびその使用
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE482946T1 (de) 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
MXPA02004366A (es) 1999-11-05 2002-11-07 Astrazeneca Ab Derivados de quinazolina como inhibidores vegf.
SK287142B6 (sk) 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
EP2079744A1 (en) * 2006-10-30 2009-07-22 Novartis AG Imidazopyridazines as pi3k lipid kinase inhibitors
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
MX2012002059A (es) * 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
EP2585468A1 (en) * 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
TWI441824B (zh) * 2010-12-16 2014-06-21 Hoffmann La Roche 三環ｐｉ３ｋ抑制劑化合物及其使用方法

Also Published As

Publication number Publication date
MX368056B (es) 2019-09-18
WO2014140644A1 (en) 2014-09-18
EP2970332A1 (en) 2016-01-20
US20160024112A1 (en) 2016-01-28
AU2014229735B2 (en) 2018-08-09
AU2014229735A1 (en) 2015-09-03
EA201591781A1 (ru) 2016-02-29
CN105051047A (zh) 2015-11-11
JP2016510803A (ja) 2016-04-11
AR095443A1 (es) 2015-10-14
EP2970332B1 (en) 2018-02-28
HRP20180839T1 (hr) 2018-06-29
US9453031B2 (en) 2016-09-27
ES2670674T3 (es) 2018-05-31
BR112015023060B1 (pt) 2022-07-05
PL2970332T3 (pl) 2018-08-31
RS57216B1 (sr) 2018-07-31
TW201446772A (zh) 2014-12-16
IL240708B (en) 2019-08-29
DK2970332T3 (en) 2018-05-22
TWI557131B (zh) 2016-11-11
KR20150129741A (ko) 2015-11-20
PH12015502159A1 (en) 2016-01-25
SG11201507555PA (en) 2015-10-29
HK1215021A1 (zh) 2016-08-12
LT2970332T (lt) 2018-06-11
KR102206318B1 (ko) 2021-01-25
IL240708A0 (en) 2015-10-29
HUE037685T2 (hu) 2018-09-28
SI2970332T1 (en) 2018-06-29
CA2904768C (en) 2021-07-27
UA118261C2 (uk) 2018-12-26
JP6379115B2 (ja) 2018-08-22
CN105051047B (zh) 2017-12-15
PE20152007A1 (es) 2016-02-04
NZ711038A (en) 2020-02-28
CA2904768A1 (en) 2014-09-18
EA029771B1 (ru) 2018-05-31
CY1120619T1 (el) 2019-12-11
CL2015002591A1 (es) 2016-02-05
PH12015502159B1 (en) 2016-01-25
MX2015011549A (es) 2016-05-31
NO2970332T3 (pt) 2018-07-28
PT2970332T (pt) 2018-05-25

Similar Documents

Publication Publication Date Title
BR112015023060A2 (pt) entidades químicas
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
UY33440A (es) ?compuestos pirimidinílicos para uso como inhibidores de atr?.
BR112015006990A2 (pt) composto, composição farmacêutica, e, uso de pelo menos um composto
BR112015011147A8 (pt) composto, composição farmacêutica, e, uso do referido composto
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
BR112015014585A2 (pt) composto, composição farmacêutica, e, método de tratamento de um ser humano
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
BR112015011148A8 (pt) composto, composição farmacêutica, e combinação
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
DOP2011000203A (es) Derivados de pirimidin indol para el tratamiento de cancer
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
BR112015024050A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112015023891A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
BR112015023858A2 (pt) composto, composição farmacêutica, e, uso de um composto
MX2016003522A (es) Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
AR093851A1 (es) Metodos para tratar la diabetes administrando un antagonista del receptor de glucagon en combinacion con un inhibidor de la absorcion del colesterol, combinacion
BR112015014855A2 (pt) compostos radiossensibilizadores para uso em combinação com radiação
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
BR112017003881A2 (pt) derivados do n-aril-2-amino-4-aril-pirimidinas poliéteres macrocíclicos como inibidores da ftl3 e jak
BR112017003880A2 (pt) derivados de poliéteres de n-aril-triciclopirimidina-2-amina macrocíclicos como inibidores de ftl3 e jak

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS